1 December 2018 - The December 2018 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The December issue of the Schedule includes a number of new/revised listings:

• Benralizumab (Fasenra) - new medicine & restriction change
  
• Deferasirox (Jadenu) - new formulation
  
• Ertuglifozin pidolate (Steglatro) - new medicine and new indication
  
• Ertuglifozin pidolate with metformin hydrochloride (Segluromet) - new combination product & new indication & new strength
  
• Golimumab (Simponi) - new indication
  
• Lanreotide acetate (Somatuline Autogel) - new indication
• Mesalazine (Ursofalk) - new strength
  
• Methotrexate sodium (Methoblastin PFS) - new formulation
  
• Midostaurin (Rydapt) - new medicine
  
• Nivolumab (Opdivo) - new indication
  
• Olaparib (Lynparza) - new formulation
  
• Sitagliptin phosphate monohydrate (Janumet) - new indication
  
• Sitagliptin phosphate monohydrate with ertuglifozin pidolate (Steglujan) - new combination product
  
• Sitagliptin phosphate monohydrate with metformin hydrochloride (Janumet, Janumet XR) - new indication
  
• Tocilizumab (Actemra ACTPen) - new formulation
  
• Trifluridine with tipiracil hydrochloride (Lonsurf) - new combination product
  

Read PBS Summary of Changes